| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 2 nov 2026Próximo | Q3 2026 | Antes de apertura | 1,38 | 3,54 B |
2 sept 2026
Henry Schein stock performance snapshot Henry Schein (HSIC) stock has drawn investor attention after recent share price moves, with the company reporting positive total returns over the past year and across multi year periods, alongside reported revenue and net income growth. At the latest share price of US$88.52, Henry Schein has given investors a 16.9% share price return over the past 90 days and a 29.4% total shareholder return over the past year. This suggests momentum has been building...
31 ago 2026
MD Sass, a boutique asset management firm, published its second-quarter investor update for its flagship, the “MD Sass Concentrated Value Strategy.” The letter can be downloaded here. In the first half of 2026, AI infrastructure stocks led the market, with the Russell 1000 Value increasing by 16.3%, outpacing the S&P 500 (10.2%) and Russell 1000 […]
25 ago 2026
HSIC vs. SAUHY: Which Stock Is the Better Value Option?
20 ago 2026
Henry Schein has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
19 ago 2026
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor Fitzgerald increases Palo Alto's target price, Morgan Stanley cuts Baidu's target price, Cantor Fitzgerald slashes Crowdstrike Holdings' target price, Baird raises Donaldson Company's target price, B of A Securities cuts Pony AI's target price.
BTIG analyst David Larsen maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $110.
18 ago 2026
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.
13 ago 2026
Henry Schein delivered a positive second quarter, with results exceeding Wall Street’s expectations and earning a strong market response. Management attributed the outperformance to accelerating internal sales growth, robust gains in its global dental merchandise segment, and early benefits from value creation initiatives. CEO Frederick Lowery emphasized the company’s success in converting occasional buyers into engaged customers and highlighted strong market share gains, particularly in the U.S
11 ago 2026
Cloud-based dental software drives margin expansion and record customer growth.
10 ago 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
6 ago 2026
HSIC vs. SAUHY: Which Stock Is the Better Value Option?
Barclays analyst Glen Santangelo maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $86 to $100.
Henry Schein, Inc. reported past Q2 2026 results with sales rising to US$3,458 million and net income to US$94 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. Importantly for long-term watchers, management also raised its 2026 total sales growth guidance, signaling greater confidence in the company’s operating initiatives and demand trends. Now we’ll examine how Henry Schein’s raised 2026 sales outlook reshapes its existing...
5 ago 2026
UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $89 to $94.
Citigroup analyst Daniel Grosslight maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $112.
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Henry Schein stock has delivered a 37.5% return over the past year, yet the valuation picture is more mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating the shares may be trading at a sizeable discount while earnings based multiples look closer to fair. Henry Schein's 37.5% one year return suggests investors have already priced in a meaningful improvement in the story, so additional upside may depend on how the fundamentals evolve from here. The leadership...
BTIG analyst David Larsen reiterates Henry Schein (NASDAQ:HSIC) with a Buy and maintains $100 price target.
Moby summary of Henry Schein, Inc.'s Q2 2026 earnings call
2026-08-05. The following slide deck was published by Henry Schein, Inc.
4 ago 2026
Henry Schein (NASDAQ:HSIC) reported higher second-quarter sales, operating margins and earnings, citing accelerating internal sales growth, market-share gains in dental merchandise and early benefits from its value-creation program. The company also raised its full-year sales and adjusted earnings g
Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call August 4, 2026 8:00 AM EDTCompany ParticipantsGraham Stanley - VP of Investor Relations & Strategic...
Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein Q2 2026: EPS $1.27 beats estimates, revenue $3.46B up 6.7%, raises full-year guidance. Stock up 1.8% premarket.
